First Clinical Study Targeting ROR1, A Cancer Stem Cell Antigen Involved In Rho-GTPase Activation
收藏干细胞与再生医学数据中心2022-02-20 更新2024-03-06 收录
下载链接：
http://data.iscr.ac.cn/Article?id=37cc705f2203c7f72a5bc6db1ea1198a
下载链接
链接失效反馈官方服务：
资源简介：
Cirmtuzumab is a humanized monoclonal antibody that selectively targets ROR1, which is expressed on cancer stem cells (CSCs). Patients experienced reversal of the stemness gene expression signature associated with oncogenic dedifferentiation, inhibition of leukemia-cell activation of Rho-GTPases and HS1, reductions in leukemia cell counts, and prolonged time-to-next-treatment (TTNT) following only 4 biweekly infusions of cirmtuzumab.
提供机构：
University of California San Diego
创建时间：
2022-02-20
